BGI Genomics, the Shenzhen genomics sequencing company, has filed to IPO on the Shenzhen Chi-Next exchange with a proposed target of raising $250 million. Late last year, the Shenzhen Exchange rejected a similar application from BGI Genomics because its documentation was not complete. The previous transaction was rumored to be much larger -- about $600 million. BGI Genomics, a division of BGI Holdings, includes several of BGI’s revenue producing divisions, such as BGI Tech, its contract genomics sequencing service subsidiary, and BGI Dx, its clinical diagnostic division.
